

**Adult CIRB - Late Phase Emphasis Meeting Agenda**

**February 17, 2022**

---

**I Continuing Review**

**A021806**, A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer (Protocol Version Date 05/04/20)

---

**II Continuing Review**

**A031701**, A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations (Protocol Version Date 01/13/21)

---

**III Continuing Review**

**A051902**, A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas (Protocol Version Date 07/02/21)

---

**IV Review**

**A081105**, Randomized Study of Erlotinib Vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) (Protocol Version Date 01/20/21)

---

**V Continuing Review**

**E3A06**, Randomized Phase III Trial of Lenalidomide versus Observation Alone In Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (Protocol Version Date 09/26/19)

---

**VI Continuing Review**

**EA5191**, A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC (Protocol Version Date 04/21/21)

---

## **VII Continuing Review**

**NRG-GI007**, Phase I Trial with Expansion Cohort of OBP-301 (Telomelysin™) and Definitive Chemoradiation for Patients with Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma Who Are Not Candidates for Surgery (Protocol Version Date 01/11/22)

---

## **VIII Continuing Review**

**NRG-GU007**, Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (Protocol Version Date 11/09/20)

---

## **IX Continuing Review**

**NRG-GY018**, A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer (Protocol Version Date 10/06/21)

---

## **X Continuing Review**

**RTOG-0724**, Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy (Protocol Version Date 02/04/22)

---

## **XI Continuing Review**

**RTOG-1112**, Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma (Protocol Version Date 09/14/20)

---

## **XII Continuing Review**

**S0819**, A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) (Protocol Version Date 10/03/16)

---

## **XIII Continuing Review**

**S1706**, A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer (Protocol Version Date 09/02/21)

**XIV Amendment**

**NRG-GU005**, Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer (Protocol Version Date 01/14/22)

---